| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
GSK620 manufacturers
- GSK620
-
-
2026-07-20
- CAS:2088410-46-0
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- GSK620
-
- $44.00
-
2026-07-17
- CAS:2088410-46-0
- Purity: 99.42%
- Supply Ability: 10g
- GSK620
-
- $1.00
-
2024-11-01
- CAS:2088410-46-0
- Min. Order: 1box
- Purity: 98%
- Supply Ability: 1
|
| Product Name: | GSK620 | | Synonyms: | GSK620;1-benzyl-N5-cyclopropyl-N3-methyl-2-oxo-1,2-dihydropyridine-3,5-dicarboxamide;Inhibitor,oral,GSK 620,phenotype,selectivity,GSK-620,whole,anti-inflammatory,GSK620,Epigenetic Reader Domain,inhibit,human,blood;3,5-Pyridinedicarboxamide, N5-cyclopropyl-1,2-dihydro-N3-methyl-2-oxo-1-(phenylmethyl)-;GSK620, 10 mM in DMSO | | CAS: | 2088410-46-0 | | MF: | C18H19N3O3 | | MW: | 325.36 | | EINECS: | | | Product Categories: | API | | Mol File: | 2088410-46-0.mol |  |
| | GSK620 Chemical Properties |
| Boiling point | 618.6±55.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 62.5 mg/mL (192.09 mM; Need ultrasonic) | | pka | 12.43±0.20(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C18H19N3O3/c1-19-17(23)15-9-13(16(22)20-14-7-8-14)11-21(18(15)24)10-12-5-3-2-4-6-12/h2-6,9,11,14H,7-8,10H2,1H3,(H,19,23)(H,20,22) | | InChIKey | QZZCUOVXHPAQRQ-UHFFFAOYSA-N | | SMILES | C1(=O)N(CC2=CC=CC=C2)C=C(C(NC2CC2)=O)C=C1C(NC)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | GSK620 Usage And Synthesis |
| Uses | GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood[1]. | | Biological Activity | GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood[1].
GSK620 shows an anti-inflammatory phenotype in human whole blood. Human blood samples are stimulated with LPS, which produces a strong immune response. The monocyte chemattractant protein 1 (MCP-1/CCL2) is measured. This is a chemokine which recruits monocytes, memory T cells, and dendritic cells to sites of inflammation. GSK620 reduces the MCP-1 response in a concentration-dependent manner with (an expected) ～1 log drop off in potency relative to the biochemical BRD4 BD2 potencies observed[1].
Highlighting the utility of GSK620 as an in vivo tool, efficacy is observed in separate models of inflammatory arthritis, psoriasis, and hepatitis[1]. | | in vitro | GSK620 shows an anti-inflammatory phenotype in human whole blood. Human blood samples are stimulated with LPS, which produces a strong immune response. The monocyte chemattractant protein 1 (MCP-1/CCL2) is measured. This is a chemokine which recruits monocytes, memory T cells, and dendritic cells to sites of inflammation. GSK620 reduces the MCP-1 response in a concentration-dependent manner with (an expected) ～1 log drop off in potency relative to the biochemical BRD4 BD2 potencies observed.
| | in vivo | Highlighting the utility of GSK620 as an in vivo tool, efficacy is observed in separate models of inflammatory arthritis, psoriasis, and hepatitis.
| | References | [1]. Seal JT, et al. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. J Med Chem. 2020;63(17):9093-9126. |
| | GSK620 Preparation Products And Raw materials |
|